Your browser doesn't support javascript.
loading
A phase 3, multicenter, single-arm, open-label study to assess the safety, tolerability, and immunogenicity of a single dose of 13-valent pneumococcal conjugate vaccine in Japanese participants aged 6-64 years who are considered to be at increased risk of pneumococcal disease and who are naive to pneumococcal vaccines.
Yamazaki, Yoshitaka; Ikeda, Masanori; Imada, Takayuki; Furuno, Kenji; Mizukami, Tomoyuki; de Solom, Richard; Shoji, Yasuko; Oe, Motoki; Aizawa, Masakazu; Giardina, Peter C; Schmoele-Thoma, Beate; Scott, Daniel A.
Afiliación
  • Yamazaki Y; Nagano Prefectural Shinshu Medical Center, Pulmonary and Infectious Diseases, Nagano, Japan. Electronic address: yoshitakayamazaki@hotmail.com.
  • Ikeda M; Department of Pediatrics, Fukuyama City Hospital, Hiroshima, Japan. Electronic address: mikeda@okayama-u.ac.jp.
  • Imada T; Nippon Kokan Fukuyama Hospital, Health Management, Hiroshima, Japan. Electronic address: tamikoru_imadafa@kki.biglobe.ne.jp.
  • Furuno K; Fukuoka Children's Hospital, General Pediatrics & Interdisciplinary Medicine, Fukuoka, Japan. Electronic address: furuno.k@fcho.jp.
  • Mizukami T; National Hospital Organization Kumamoto Medical Center, Pediatrics, Kumamoto, Japan. Electronic address: mizukami.tomoyuki.tg@mail.hosp.go.jp.
  • de Solom R; Vaccine Clinical Research & Development Australia, Pfizer Australia, Sydney, NSW, Australia. Electronic address: richard.desolom@pfizer.com.
  • Shoji Y; Vaccine Research and Development, Pfizer R&D Japan G.K., Tokyo, Japan. Electronic address: yasuko.shoji@pfizer.com.
  • Oe M; Vaccine Research and Development, Pfizer R&D Japan G.K., Tokyo, Japan. Electronic address: motoki.oe@pfizer.com.
  • Aizawa M; Vaccine Research and Development, Pfizer R&D Japan G.K., Tokyo, Japan. Electronic address: masakazu.aizawa@pfizer.com.
  • Giardina PC; Vaccine Clinical Research and Development, Pfizer Inc, Pearl River, NY, USA. Electronic address: peter.giardina@pfizer.com.
  • Schmoele-Thoma B; Vaccine Clinical Research and Development, Pfizer Pharma GmbH, Berlin, Germany. Electronic address: Beate.Schmoele-Thoma@Pfizer.com.
  • Scott DA; Vaccine Clinical Research and Development, Pfizer Inc, Collegeville, PA, USA. Electronic address: dan.scott@pfizer.com.
Vaccine ; 39(43): 6414-6421, 2021 10 15.
Article en En | MEDLINE | ID: mdl-34563397
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones Neumocócicas / Vacunas Neumococicas / Anticuerpos Antibacterianos Tipo de estudio: Clinical_trials / Etiology_studies / Risk_factors_studies Límite: Adolescent / Adult / Child / Humans / Middle aged País/Región como asunto: Asia Idioma: En Revista: Vaccine Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones Neumocócicas / Vacunas Neumococicas / Anticuerpos Antibacterianos Tipo de estudio: Clinical_trials / Etiology_studies / Risk_factors_studies Límite: Adolescent / Adult / Child / Humans / Middle aged País/Región como asunto: Asia Idioma: En Revista: Vaccine Año: 2021 Tipo del documento: Article